TOPAZ─1 phase III trial shows AstraZeneca's Imfinzi plus chemotherapy doubled OS rate at three years for patients with ...
Updated exploratory results from the TOPAZ-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for …